WGSWW — GeneDx Holdings Corp.

Summary of GeneDx Holdings Corp. Q1 2026 Earnings Call

1. Key Financial Results and Metrics

• Total Revenue: $102.3 million, including $90.6 million from exome and genome testing, up 27% year-over-year.
• Test Volume: 27,488 tests, reflecting a 34% increase year-over-year.
• Blended Average Reimbursement Rate (ARR): Approximately $3,300, impacted by product mix.
• Adjusted Gross Margin: 69%.
• Adjusted Net Loss: $8.2 million.
• Revenue Guidance for 2026: Revised to $475 million to $490 million, down from previous estimates.

2. Strategic Updates and Business Highlights

• GeneDx is shifting focus from multi-gene panels to comprehensive exome and genome testing.
• The company reported strong demand in foundational markets and positive early momentum in expansion markets.
• Integration of the Fabric Genomics acquisition is ongoing, with a focus on international growth.
• The launch of the Reflex offering in February aims to balance clinical demand with higher gross margin products.
• The sales force has been expanded to enhance market penetration across various segments, including NICU and general pediatrics.

3. Forward Guidance and Outlook

• Expected exome and genome volume growth of at least 30%, translating to approximately 126,400 tests.
• Anticipated adjusted gross margin of around 70%.
• Projected adjusted net loss of approximately $5 million for Q2 2026, with a return to profitability expected in Q3 2026.
• Continued focus on optimizing unit economics and improving reimbursement dynamics.

4. Bad News, Challenges, or Points of Concern

• Revenue was $12 million below expectations due to a lower-than-expected blended ARR and weaker performance from non-core business lines.
• The company has reduced its revenue expectations for 2026 by 12%, indicating challenges in achieving prior growth forecasts.
• The transition to genome testing is slower than anticipated, with reimbursement rates for genome testing significantly lower than for exome testing.
• The integration of the Fabric business has faced challenges, leading to a $31.3 million non-cash impairment charge.

5. Notable Q&A Insights

• Management acknowledged the need for improved forecasting precision and tighter channel management to stabilize ARR.
• There is confidence in the long-term potential of the biopharma segment, despite longer sales cycles impacting short-term revenue.
• The company is focused on enhancing sales force productivity and addressing execution issues related to parental comparator samples.
• Competitive dynamics remain stable, with no significant threats identified from new entrants in the market.
• Management emphasized the importance of controlling internal factors, such as cost of goods sold (COGS) and revenue cycle management, to improve profitability over time.

Overall, while GeneDx Holdings Corp. has demonstrated strong test volume growth and strategic initiatives to enhance its market position, it faces challenges in revenue realization and reimbursement dynamics that have led to a cautious outlook for the remainder of 2026.